300199Hybio Pharmaceutical300199 info
$1.27info-0.66%24h
Global rank7331
Market cap$1.12B
Change 7d-1.32%
YTD Performance-33.65%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Hybio Pharmaceutical (300199) Stock Overview

    Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.

    300199 Stock Information

    Symbol
    300199
    Address
    Hanyu Biological Park, No. 37Shenzhen, 518057China
    Founded
    -
    Trading hours
    -
    Website
    https://www.hybio.com.cn
    Country
    🇨🇳 China
    Phone Number
    86 755 2658 8000

    Hybio Pharmaceutical (300199) Price Chart

    -
    Value:-

    Hybio Pharmaceutical Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.27
    N/A
    Market Cap
    $1.12B
    N/A
    Shares Outstanding
    883.24M
    N/A
    Employees
    975.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org